Remove 2030 Remove Disease Remove Vaccine
article thumbnail

Q&A: One scientist’s bold vision to make on-demand treatments routine for life-threatening rare genetic diseases

Broad Institute

Based on a technology developed by Broad Institute core member David Liu’s laboratory, the treatment is the first in a series of new medicines being tested to treat rare diseases by repairing patients’ particular genetic misspellings. s to be produced at scale, making them the standard of care for life-threatening rare genetic diseases.

article thumbnail

mRNA Tech Transfer Phase 2.0 Discussed at G20 Summit

The Pharma Data

This meant putting the fundamentals of mRNA production directly into the hands of local innovators — a dramatic departure from previous models that kept much of vaccine production within a small number of firms in high-income settings. 2026–2030). mRNA Technology Transfer Programme Moves Into Phase 2.0,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Long Road to End Tuberculosis

Codon

Physicians working in the early 20th century had little choice but to treat the world’s most rampant infectious disease with methods such as these. Even after microbiologists discovered the bacterium that causes the illness in 1882, it wasn’t until the 1920s that researchers were able to develop a vaccine for TB.

article thumbnail

Price of World’s First Malaria Vaccine for Children in Endemic Countries Slashed by Over 50%, Now Under $5

The Pharma Data

This announcement was made as part of their pledges to Gavi, the Vaccine Alliance, ahead of Gavi’s sixth replenishment cycle (Gavi 6.0) scheduled for 2026 to 2030. In a landmark move, Bharat Biotech will progressively reduce the price of the RTS,S vaccine to below $5 per dose by 2028—a reduction of more than 50%.

article thumbnail

Immunization at Every Stage of Life: A Key to Lifelong Health

The Pharma Data

A Life-Course Approach to Immunization: Prioritizing Vaccination at Every Age to Unlock the Full Potential of Lifelong Health In a striking demographic milestone, the global population is undergoing a historic transformation: for the first time ever, the number of adults over the age of 65 now exceeds that of children under the age of five.

article thumbnail

Abivax stock soars on trial data for ulcerative colitis drug

BioPharma Drive: Drug Pricing

Dive Insight: Abivax’s drug is the first in its class and offers another way to treat a disease that is increasingly attracting attention from drugmakers. The new Abivax studies have pushed obefazimod to the front of the field for oral drugs that treat inflammatory bowel disease, Leerink Partners analyst Thomas J. Merck & Co.

article thumbnail

COVAX ANNOUNCES ADDITIONAL DEALS TO ACCESS PROMISING COVID-19 VACCINE CANDIDATES; PLANS GLOBAL ROLLOUT STARTING Q1 2021

The Pharma Data

COVAX now has agreements in place to access nearly two billion doses of several promising vaccine candidates, and laid the groundwork for further doses to be secured through contributions from donors. billion donor-funded doses of approved vaccines in 2021 to the 92 low- and middle-income economies eligible for the COVAX AMC.